Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
3 Up-and-Coming Growth Stocks to Buy Right Now
06:00am, Saturday, 25'th Mar 2023
Axsome already has two approved drugs and could add two more in the near future. Sarepta has significant growth opportunities with its rare-disease drugs.
Why did Sarepta Therapeutics Stock Plummet?
08:01am, Tuesday, 21'st Mar 2023
The middle of March may be when many people celebrate St. Patrick's Day, but it was an unlucky time for Sarepta Therapeutics (NASDAQ: SRPT). Unfortunately, the United States Food and Drug Administrati
Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?
04:37am, Tuesday, 21'st Mar 2023
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n
Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001
04:02pm, Friday, 17'th Mar 2023
Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.
Why Is Sarepta Therapeutics (SRPT) Stock Down 20% Today?
09:30am, Friday, 17'th Mar 2023
Sarepta Therapeutics (NASDAQ: SRPT ) stock is sliding lower on Friday after the company announced an advisory committee meeting with the FDA. According to a press release, the company will meet with t
Sarepta Crashes On An Unexpected Roadblock For Its Gene Therapy
09:21am, Friday, 17'th Mar 2023
In a surprise decision, the FDA will hold an advisory committee to discuss Sarepta's gene therapy, and SRPT stock tanked Friday. The post Sarepta Crashes On An Unexpected Roadblock For Its Gene Therap
Sarepta Therapeutics plummets 20% after FDA contradicts company and requires advisory meeting
06:16pm, Thursday, 16'th Mar 2023
Sarepta Therapeutics Inc. SRPT shares plummeted in the extended session Thursday after the Food and Drug Administration contradicted the biotech company and said it required an advisory committee meet
2 Biotech Stocks To Watch In March 2022
05:52pm, Thursday, 16'th Mar 2023
Check out these 2 biotech stocks in the stock market today.
Sarepta Therapeutics: Time To Change My Game Plan After Q4 Earnings
09:00am, Saturday, 04'th Mar 2023
Sarepta Therapeutics recently reported their Q4 and full-year 2022 earnings with a minor miss on EPS and a solid beat on revenue. The market reacted positively moving SRPT up. The company continues to
Why Sarepta Therapeutics' Shares Rose 23.4% This Week
03:26pm, Thursday, 02'nd Mar 2023
The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval.
Sarepta's stock still up after Tuesday's announcement that its Duchenne drug candidate won't require a FDA AdCom meeting
02:45pm, Wednesday, 01'st Mar 2023
Shares of Sarepta Therapeutics Inc. SRPT were up 18.7% in trading on Wednesday afternoon, a day after the company told investors that the Food and Drug Administration does not plan to schedule an advi
Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up
12:47pm, Wednesday, 01'st Mar 2023
Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.
Sarepta Therapeutics pops as results top estimates and Morgan Stanley raises share price to $187
12:46pm, Wednesday, 01'st Mar 2023
Sarepta Therapeutics Inc (NASDAQ:SRPT) stock rocketed after the drug company posted fourth quarter financial results that topped Wall Street estimates and Morgan Stanley (NYSE:MS) said the stock could
Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy
10:01am, Wednesday, 01'st Mar 2023
Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy, analysts suggested Wednesday as SRPT stock rocketed. The post Sarepta Rockets And Breaks Out As FDA Smooths The Path
Why Is Sarepta Therapeutics (SRPT) Stock Up 21% Today?
09:49am, Wednesday, 01'st Mar 2023
Sarepta Therapeutics (NASDAQ: SRPT ) stock is heading higher on Wednesday following the release of its latest earnings report. For the fourth quarter of 2022, Sarepta Therapeutics reported adjusted ea
